Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Efficacy and Safety of Multiple Doses of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease

NCT07848880 is registered in ClinicalTrials.gov with Zhejiang Doer Biologics Co., Ltd. as lead sponsor.

NCT NCT07848880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07848880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Efficacy and Safety of Multiple Doses of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
Lead sponsor
Zhejiang Doer Biologics Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2029
Enrollment
315 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia